Jan 13, 2021
UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy
Nov 18, 2020
UCB unleashes the power of data in new collaboration
Nov 12, 2020
UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms
Oct 31, 2020
Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients
Oct 29, 2020
UCB Presents Nine Abstracts at EADV 2020, Showcasing Ongoing Commitment to Dermatology
Aug 31, 2020
Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry
Jul 24, 2020
Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance
Jul 07, 2020
UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Jun 24, 2020
UCB Announces New Data from its Epilepsy Portfolio Presented on the American Academy of Neurology Virtual Platform
Dec 05, 2019
UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting
Nov 25, 2019
UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.
Nov 15, 2019
Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Jun 04, 2019
UCB Boston Research is Advancing Medical Innovation
May 20, 2019
UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.
Mar 28, 2019
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
Mar 11, 2019
Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)
Mar 01, 2019
New Data Affirms Strength of UCB Immuno-Dermatology Portfolio
Oct 23, 2018
Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients
Aug 13, 2018
FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters
Apr 20, 2018
UCB's Commitment in Neurology